Percentage change from baseline in absolute lymphocyte counts at day 28 following treatment with CDP323 for 28 days (per protocol population).

an = 14 per group except for CD34+ cells, where n = 5 for placebo and CDP323 1000 mg bid and n = 4 for CDP323 100 mg bid, CDP323 500 mg bid, and CDP323 1000 mg qd.bLeast squares mean from analysis of variance (ANOVA).cStatistical comparisons were made using univariate ANOVA.bid = twice daily; CI = confidence interval; NK = natural killer; NR = not reported (linear trend test for dose-response relationship was not statistically significant); qd = once daily.Note: For all lymphocyte types, differences between the 500-mg bid and 1000-mg qd dosages were not statistically significant and are not displayed in this table.